Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 9/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44346 | 0.89 | — | — | |
| SCHEMBL6437613 | 0.87 | — | — | |
| Monoethanolamine SCHEMBL8362647 | 0.80 | ANPEP (0.56) | ANPEPERAP2LAP3LMNAALDH1A1 | |
| SCHEMBL17785520 | 0.80 | ANPEP (0.50) | ANPEPERAP2LAP3ERAP1 | |
| Glycerin SCHEMBL28668153 | 0.78 | LMNA (0.56) | ANPEPERAP2LAP3LMNAALDH1A1 | |
| Glycerin SCHEMBL888512 | 0.78 | LMNA (0.64) | ANPEPERAP2LMNAALDH1A1 | |
| Glycerin SCHEMBL31106042 | 0.78 | LMNA (0.64) | ANPEPERAP2LMNAALDH1A1 | |
| Glycerin SCHEMBL21101 | 0.78 | LMNA (0.64) | ANPEPERAP2LMNAALDH1A1 | |
| Glycerin SCHEMBL188342 | 0.78 | LMNA (0.64) | ANPEPERAP2LMNAALDH1A1 | |
| Glycerin SCHEMBL30710214 | 0.78 | LMNA (0.64) | ANPEPERAP2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835619-B1 | Targeted therapy to repolarize tumor-associated macrophages (TAMs) | VERILY LIFE SCIENCES LLC (US) | 2020-11-17 | — | — | US | claimed |
| US-10751284-B1 | Targeted therapy to deplete tumor-associated macrophages (TAMs) | VERILY LIFE SCIENCES LLC (US) | 2020-08-25 | — | — | US | claimed |
| CN-102652015-B | Pharmaceutical composition comprising oligopeptides, preferably cilengitide | 默克专利有限公司 | 2016-08-03 | — | — | CN | claimed |
| CN-102652015-A | Pharmaceutical composition comprising oligopeptides, preferably cilengitide | MERCK PATENT GMBH | 2012-08-29 | — | — | CN | claimed |
| EP-4358952-A1 | <SMALLCAPS/>? ? ?IN VIVO? ? ? ? ?INDOCARBOCYANINE LIPID DERIVATIVES FORCARGO DELIVERY | The Regents of the University of Colorado, a body corporate (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271671-A1 | INDOCARBOCYANINE LIPID DERIVATIVES FOR IN VIVO CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-109880858-B | Method for reducing content of free fatty acid in marine phospholipid | 威海深蓝奇迹生物科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11318097-B1 | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages | VERILY LIFE SCIENCES LLC (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114008455-A | Identification of endometriotic tissue using mass spectrometry | 得克萨斯大学体系董事会 | 2022-02-01 | — | — | CN | disclosed |
| US-11179335-B1 | ROS-responsive liposomes for specific targeting | VERILY LIFE SCIENCES LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-10835619-B1 | Targeted therapy to repolarize tumor-associated macrophages (TAMs) | VERILY LIFE SCIENCES LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-10751284-B1 | Targeted therapy to deplete tumor-associated macrophages (TAMs) | VERILY LIFE SCIENCES LLC (US) | 2020-08-25 | — | — | US | disclosed |
| CN-104349782-A | Vesicular formulations | SEQUESSOME TECHNOLOGY HOLDINGS LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-102652015-A | Pharmaceutical composition comprising oligopeptides, preferably cilengitide | MERCK PATENT GMBH | 2012-08-29 | — | — | CN | disclosed |
| US-20120108944-A1 | In Vivo 1H Magnetic Resonance Spectroscopy For The Diagnosis Of Testicular Function And Disease | The Regeents of the University of California (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2421434-A1 | IN VIVO 1H MAGNETIC RESONANCE SPECTROSCOPY FOR THE DIAGNOSIS OF TESTICULAR FUNCTION AND DISEASE | The Regents of the University of California (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010124134-A2 | IN VIVO1H MAGNETIC RESONANCE SPECTROSCOPY FOR THE DIAGNOSIS OF TESTICULAR FUNCTION AND DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | disclosed |
| CN-101309707-A | Composition comprising lipoxygenase inhibitor and cyclodextrin | BAXTER INT (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1364224-A1 | MAGNETIC RESONANCE SPECTROSCOPY TO IDENTIFY AND CLASSIFY MICROORGANISMS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002067005-A1 | MAGNETIC RESONANCE SPECTROSCOPY TO IDENTIFY AND CLASSIFY MICROORGANISMS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-08-29 | — | — | WO | disclosed |